Eyes with CSME | Eyes without CSME | |||||||
IVTA group | IVB group | PRP group | p Value | IVTA group | IVB group | PRP group | p Value | |
Number of eyes (n) | 16 | 16 | 14 | 14 | 15 | 16 | ||
Systemic | ||||||||
Age (years) | 49.8 (11.1) | 51.2 (34.8) | 51.1 (21.7) | 0.231 | 52.0 (13.2) | 50.5 (10.1) | 50.9 (19.3) | 0.132 |
Female (%) | 31.25 | 37.5 | 35.71 | 28.57 | 33.33 | 31.25 | ||
Duration of DM (months) | 168.2 (25.4) | 153.7 (22.1) | 158.7 (21.1) | 0.658 | 154.5 (21.1) | 160.8 (19.3) | 155.5 (24.1) | 0.832 |
HbA1c (%) | 6.91 (0.21) | 7.81 (0.32) | 7.31 (0.41) | 0.815 | 7.12 (0.13) | 7.21 (0.23) | 7.18 (0.09) | 0.651 |
Systolic BP (mm Hg) | 141 (21) | 143 (15) | 140 (18) | 0.258 | 138 (18) | 140 (16) | 145 (19) | 0.815 |
Diastolic BP (mm Hg) | 96 (14) | 91 (17) | 98 (15) | 0.543 | 98 (15) | 98 (13) | 100 (21) | 0.983 |
Ocular | ||||||||
BCVA (logMAR) | 0.33 (0.16) | 0.34 (0.16) | 0.34 (0.17) | 0.814 | 0.20 (0.15) | 0.22 (0.28) | 0.19 (0.21) | 0.715 |
IOP (mm Hg) | 17.2 (3.5) | 16.0 (1.9) | 15.3 (2.1) | 0.758 | 16.8 (2.7) | 15.9 (4.1) | 16.7 (3.3) | 0.427 |
CMT (μm) | 463.50 (227.47) | 443.22 (169.72) | 459.43 (168.85) | 0.654 | 207.20 (30.77) | 205.15 (25.30) | 209.75 (38.85) | 0.681 |
PRP | ||||||||
Power (mW) | 242 (20.8) | 238 (21.7) | 243 (20.7) | 0.578 | 251 (19.1) | 244 (22.1) | 248 (20.5) | 0.310 |
Number of burns (n) | 1329 (45.2) | 1351 (35.6) | 1339 (28.8) | 0.719 | 1335 (31.8) | 1381 (41.8) | 1348 (35.8) | 0.618 |
Values are mean±SD.
There were no statistically significant differences between the three groups.
BCVA, best corrected visual acuity; BP, blood pressure; CMT, central macular thickness; CSME, clinically significant macular oedema; DM, diabetic mellitus; HbA1c, glycated haemoglobin; IOP, intraocular pressure; IVB, intravitreal bevacizumab; IVTA, intravitreal triamcinolone acetonide.